Blog
About

0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Losses of 1,25- and 24,25-Dihydroxycholecalciferol in the Peritoneal Fluid of Patients Treated with Continuous Ambulatory Peritoneal Dialysis

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          We measured peritoneal losses of the active vitamin D metabolites 1,25(OH)<sub>2</sub>D<sub>3</sub> and 24,25(OH)<sub>2</sub>D<sub>3</sub> in patients receiving continuous ambulatory peritoneal dialysis (CAPD). The serum concentration of 24,25(OH)<sub>2</sub>D<sub>3</sub> was considerably lower than in hemodialysis patients. The serum concentration of 1,25(OH)<sub>2</sub>D<sub>3</sub> was undetectable and rose to levels similar to those in hemodialysis patients only after loading with much higher oral doses of 1-α-vitamin D<sub>3</sub> than those received by hemodialysis patients. Losses of both metabolites in peritoneal fluid were considerable, averaging approximately 6–8% of the plasma pool per day. These losses lead to low serum levels of these active vitamin D metabolites in CAPD patients, which may be an important factor in exacerbating renal osteodystrophy. Our results indicate the need for increased replacement doses of vitamin D metabolites in CAPD patients.

          Related collections

          Author and article information

          Journal
          NEF
          Nephron
          10.1159/issn.1660-8151
          Nephron
          S. Karger AG
          1660-8151
          2235-3186
          1984
          1984
          03 December 2008
          : 36
          : 2
          : 111-113
          Affiliations
          Department of Nephrology and Toor Institute, Soroka University Hospital and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheba, Israel
          Article
          183128 Nephron 1984;36:111–113
          10.1159/000183128
          6607420
          © 1984 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 3
          Categories
          Original Paper

          Comments

          Comment on this article